Do analysts rate KROS or INMB?

Keros Therapeutics currently has a consensus target price of $20.50, indicating a potential upside of 91.77%. Given Keros Therapeutics' higher probable upside, research analysts clearly believe Keros Therapeutics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media refer more to KROS or INMB?

In the previous week, Keros Therapeutics had 9 more articles in the media than INmune Bio. MarketBeat recorded 18 mentions for Keros Therapeutics and 9 mentions for INmune Bio. INmune Bio's average media sentiment score of 0.54 beat Keros Therapeutics' score of -0.11 indicating that INmune Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral INmune Bio 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend INMB or GLSI?

Greenwich LifeSciences has a consensus price target of $57.00, indicating a potential upside of 267.74%. Given Greenwich LifeSciences' higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Greenwich LifeSciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is INMB or GLSI more profitable?

INmune Bio's return on equity of -82.87% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Greenwich LifeSciences N/A -941.15% -368.53%

Does the media refer more to INMB or GLSI?

In the previous week, INmune Bio had 6 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 9 mentions for INmune Bio and 3 mentions for Greenwich LifeSciences. INmune Bio's average media sentiment score of 0.54 beat Greenwich LifeSciences' score of 0.00 indicating that INmune Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Greenwich LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate INMB or WHWK?

Whitehawk Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 80.22%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Whitehawk Therapeutics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Whitehawk Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Is INMB or WHWK more profitable?

Whitehawk Therapeutics' return on equity of -58.46% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Whitehawk Therapeutics N/A -58.46% -53.81%

Does the media favor INMB or WHWK?

In the previous week, INmune Bio had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 9 mentions for INmune Bio and 7 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.63 beat INmune Bio's score of 0.54 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Whitehawk Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PYXS or INMB?

Pyxis Oncology presently has a consensus target price of $7.50, suggesting a potential upside of 95.82%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Pyxis Oncology is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is PYXS or INMB more profitable?

INmune Bio's return on equity of -82.87% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% INmune Bio N/A -82.87% -62.23%

Does the media prefer PYXS or INMB?

In the previous week, INmune Bio had 5 more articles in the media than Pyxis Oncology. MarketBeat recorded 9 mentions for INmune Bio and 4 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.63 beat INmune Bio's score of 0.54 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RNA or INMB?

Avidity Biosciences presently has a consensus price target of $63.85, indicating a potential upside of 421.62%. Given Avidity Biosciences' higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 1 Sell rating(s) 11 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.29 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is RNA or INMB more profitable?

Avidity Biosciences' return on equity of 0.00% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets Avidity Biosciences N/A N/A N/A INmune Bio N/A -82.87% -62.23%

Does the media favor RNA or INMB?

In the previous week, Avidity Biosciences had 6 more articles in the media than INmune Bio. MarketBeat recorded 15 mentions for Avidity Biosciences and 9 mentions for INmune Bio. Avidity Biosciences' average media sentiment score of 0.90 beat INmune Bio's score of 0.54 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

INmune Bio (INMB) Competitors

$2.12 +0.03 (+1.44%)

As of 04:00 PM Eastern

Compare

INMB vs. KROS, GLSI, WHWK, PYXS, and RNA

Should you buy INmune Bio stock or one of its competitors? INmune Bio's main competitors and comparable companies include Keros Therapeutics (KROS), Greenwich LifeSciences (GLSI), Whitehawk Therapeutics (WHWK), Pyxis Oncology (PYXS), and Avidity Biosciences (RNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does INmune Bio compare to Keros Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Keros Therapeutics has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.87	$87.01M	-$3.70	N/A
INmune Bio	$50K	1,126.99	-$45.93M	-$0.67	N/A

Keros Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Keros Therapeutics currently has a consensus target price of $20.50, indicating a potential upside of 91.77%. Given Keros Therapeutics' higher probable upside, research analysts clearly believe Keros Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Keros Therapeutics had 9 more articles in the media than INmune Bio. MarketBeat recorded 18 mentions for Keros Therapeutics and 9 mentions for INmune Bio. INmune Bio's average media sentiment score of 0.54 beat Keros Therapeutics' score of -0.11 indicating that INmune Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
INmune Bio	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 12.6% of Keros Therapeutics shares are owned by insiders. Comparatively, 21.4% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

INmune Bio has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-21.40%	-19.79%
INmune Bio	N/A	-82.87%	-62.23%

Summary

Keros Therapeutics beats INmune Bio on 10 of the 17 factors compared between the two stocks.

How does INmune Bio compare to Greenwich LifeSciences?

INmune Bio (NASDAQ:INMB) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

INmune Bio has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 21.4% of INmune Bio shares are held by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

INmune Bio's return on equity of -82.87% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Greenwich LifeSciences	N/A	-941.15%	-368.53%

Greenwich LifeSciences has a consensus price target of $57.00, indicating a potential upside of 267.74%. Given Greenwich LifeSciences' higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Greenwich LifeSciences has lower revenue, but higher earnings than INmune Bio. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,126.99	-$45.93M	-$0.67	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

In the previous week, INmune Bio had 6 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 9 mentions for INmune Bio and 3 mentions for Greenwich LifeSciences. INmune Bio's average media sentiment score of 0.54 beat Greenwich LifeSciences' score of 0.00 indicating that INmune Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Greenwich LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

INmune Bio beats Greenwich LifeSciences on 10 of the 15 factors compared between the two stocks.

How does INmune Bio compare to Whitehawk Therapeutics?

INmune Bio (NASDAQ:INMB) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Whitehawk Therapeutics' return on equity of -58.46% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Whitehawk Therapeutics	N/A	-58.46%	-53.81%

Whitehawk Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 80.22%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Whitehawk Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Whitehawk Therapeutics has lower revenue, but higher earnings than INmune Bio. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,126.99	-$45.93M	-$0.67	N/A
Whitehawk Therapeutics	N/A	N/A	-$20.60M	-$1.12	N/A

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

INmune Bio has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

In the previous week, INmune Bio had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 9 mentions for INmune Bio and 7 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.63 beat INmune Bio's score of 0.54 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Whitehawk Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Whitehawk Therapeutics beats INmune Bio on 9 of the 15 factors compared between the two stocks.

How does INmune Bio compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by company insiders. Comparatively, 21.4% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Pyxis Oncology presently has a consensus target price of $7.50, suggesting a potential upside of 95.82%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Pyxis Oncology is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, INmune Bio had 5 more articles in the media than Pyxis Oncology. MarketBeat recorded 9 mentions for INmune Bio and 4 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.63 beat INmune Bio's score of 0.54 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
INmune Bio	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pyxis Oncology has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

INmune Bio's return on equity of -82.87% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
INmune Bio	N/A	-82.87%	-62.23%

INmune Bio has lower revenue, but higher earnings than Pyxis Oncology. INmune Bio is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	17.51	-$79.62M	-$1.31	N/A
INmune Bio	$50K	1,126.99	-$45.93M	-$0.67	N/A

Summary

Pyxis Oncology and INmune Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does INmune Bio compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Avidity Biosciences presently has a consensus price target of $63.85, indicating a potential upside of 421.62%. Given Avidity Biosciences' higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

12.7% of INmune Bio shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by company insiders. Comparatively, 21.4% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Avidity Biosciences has higher revenue and earnings than INmune Bio. Avidity Biosciences is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$36.68M	5.71	-$16.59M	-$0.97	N/A
INmune Bio	$50K	1,126.99	-$45.93M	-$0.67	N/A

In the previous week, Avidity Biosciences had 6 more articles in the media than INmune Bio. MarketBeat recorded 15 mentions for Avidity Biosciences and 9 mentions for INmune Bio. Avidity Biosciences' average media sentiment score of 0.90 beat INmune Bio's score of 0.54 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
INmune Bio	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avidity Biosciences' return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	N/A	N/A	N/A
INmune Bio	N/A	-82.87%	-62.23%

Summary

Avidity Biosciences beats INmune Bio on 8 of the 14 factors compared between the two stocks.

Get INmune Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INMB vs. The Competition

Export

Metric	INmune Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$56.35M	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-3.16	9.13	269.75	24.74
Price / Sales	1,126.99	1,274.20	652.34	108.60
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	2.41	17.66	11.27	6.42
Net Income	-$45.93M	-$13.25M	$3.45B	$347.12M
7 Day Performance	14.59%	5.36%	3.56%	2.48%
1 Month Performance	9.28%	-1.74%	-0.58%	-1.04%
1 Year Performance	-17.19%	61.36%	77.52%	23.22%

INmune Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INMB INmune Bio	1.0822 of 5 stars	$2.12 +1.4%	N/A	-18.6%	$56.35M	$50K	N/A	10	Earnings Report Analyst Upgrade
KROS Keros Therapeutics	3.0701 of 5 stars	$10.24 +1.3%	$20.50 +100.2%	-18.8%	$201.86M	$244.06M	N/A	100	Earnings Report Analyst Upgrade Gap Down
GLSI Greenwich LifeSciences	2.043 of 5 stars	$13.79 +1.8%	$57.00 +313.3%	+17.9%	$200.91M	N/A	N/A	3	Upcoming Earnings Gap Up
WHWK Whitehawk Therapeutics	2.4637 of 5 stars	$4.05 +2.1%	$8.20 +102.7%	+172.0%	$198.80M	N/A	N/A	21	Earnings Report Analyst Upgrade
PYXS Pyxis Oncology	3.1566 of 5 stars	$3.11 +2.4%	$7.50 +140.9%	+251.9%	$196.70M	$13.86M	N/A	60	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INMB) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

INmune Bio (INMB) Competitors

INMB vs. KROS, GLSI, WHWK, PYXS, and RNA

How does INmune Bio compare to Keros Therapeutics?

Summary

How does INmune Bio compare to Greenwich LifeSciences?

Summary

How does INmune Bio compare to Whitehawk Therapeutics?

Summary

How does INmune Bio compare to Pyxis Oncology?

Summary

How does INmune Bio compare to Avidity Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

INmune Bio (INMB) Competitors

INMB vs. KROS, GLSI, WHWK, PYXS, and RNA

How does INmune Bio compare to Keros Therapeutics?

Which has stronger valuation & earnings, KROS or INMB?

Which has more volatility and risk, KROS or INMB?

Do analysts rate KROS or INMB?

Does the media refer more to KROS or INMB?

Do institutionals and insiders hold more shares of KROS or INMB?

Is KROS or INMB more profitable?

Summary

How does INmune Bio compare to Greenwich LifeSciences?

Which has more volatility and risk, INMB or GLSI?

Do institutionals & insiders hold more shares of INMB or GLSI?

Is INMB or GLSI more profitable?

Do analysts recommend INMB or GLSI?

Which has stronger earnings & valuation, INMB or GLSI?

Does the media refer more to INMB or GLSI?

Summary

How does INmune Bio compare to Whitehawk Therapeutics?

Is INMB or WHWK more profitable?

Do analysts rate INMB or WHWK?

Which has stronger earnings and valuation, INMB or WHWK?

Do institutionals and insiders hold more shares of INMB or WHWK?

Which has more risk and volatility, INMB or WHWK?

Does the media favor INMB or WHWK?

Summary

How does INmune Bio compare to Pyxis Oncology?

Do institutionals & insiders have more ownership in PYXS or INMB?

Do analysts rate PYXS or INMB?

Does the media prefer PYXS or INMB?

Which has more risk & volatility, PYXS or INMB?

Is PYXS or INMB more profitable?

Which has stronger valuation and earnings, PYXS or INMB?

Summary

How does INmune Bio compare to Avidity Biosciences?

Do analysts rate RNA or INMB?

Do institutionals and insiders believe in RNA or INMB?

Which has preferable valuation and earnings, RNA or INMB?

Does the media favor RNA or INMB?

Is RNA or INMB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools